Stopped: Financial reasons
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
Age range
18 Years – 120 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)
Timeframe: Day 1 through 90 days after the last dose of study drug
Incidence and Severity of Adverse Events of Special Interest (AESIs)
Timeframe: Day 1 through 90 days after the last dose of study drug
Number of Participants With Clinically Significant Changes in Laboratory Parameters
Timeframe: Day 1 through 90 days after the last dose of study drug
Incidence of Dose-limiting Toxicities (DLTs)
Timeframe: Day 1 through Day 28 of first dose
Maximum Tolerated dose (MTD)
Timeframe: Day 1 through Day 28 of first dose
Recommended Phase 2 Dose (RP2D)
Timeframe: Day 1 through Day 28 of first dose